Taribavirin in the treatment of hepatitis C

Bibliography

• Lavanchy D. The global burden of hepatitis C. Liver Int 2009;29(s1):74-81
   PubMed Web of Science ®Google Scholar
• Bain VG, Lee SS, Peltekian K, Clinical trial: exposure to ribavirin predicts EVR and SVR in patients with HCV genotype 1 infection treated with peginterferon alpha-2a plus ribavirin. Aliment Pharmacol Ther 2008;28(1):43-50
   PubMed Web of Science ®Google Scholar
• Micromedex® Healthcare Series [Internet database]. Thompson Reuters (Healthcare), Inc; Greenwood Village, Colo; Updated periodically
   Google Scholar
• Balan V, Schwartz D, Wu GJ, Erythropoietic response to anemia in chronic hepatitis C patients receiving combination pegylated interferon/ribavirin. Am J Gastroenterol 2005;100:299-307
   PubMed Web of Science ®Google Scholar
• Sulkowski MS, Wasserman R, Brooks L, Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection. J Viral Hepat 2004;11:243-50
   PubMed Web of Science ®Google Scholar
• Shiffman ML, Salvatore J, Hubbard S, Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha. Hepatology 2007;46:371-9
   PubMed Web of Science ®Google Scholar
• Dieterich DT, Wasserman R, Brau N, Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa. Am J Gastroenterol 2003;98:2491-2
   PubMed Web of Science ®Google Scholar
• Afdahl NH. Role of epoetin alfa in maintaining ribavirin dose. Gastroenterol Clin North Am 2004;33:S25-35
   Google Scholar
• Gish RG. Treating HCV with ribavirin analogues and ribavirin-like molecules. J Antimicrob Chemother 2006;57:8-13
   PubMed Web of Science ®Google Scholar
• Wu JZ, Larson G, Walker H. Phosphorylation of ribavirin and viramidine by adenosine kinase and cytosolic 5'-nucleotidase II: implications for ribavirin metabolism in erythrocytes. Antimicrob Agents Chemother 2005;49(6):2164-71
   PubMed Web of Science ®Google Scholar
• Wu JZ, Lin CC, Hong Z. Ribavirin, viramidine and adenosine-deaminase-catalysed drug activation: implication for nucleoside prodrug design. J Antimicrob Chemother 2003;52:543-6
   PubMed Web of Science ®Google Scholar
• Wu JZ, Larson G, Hong Z. Dual-action mechanism of viramidine functioning as a prodrug and as a catabolic inhibitor for ribavirin. Antimicrob Agents Chemother 2004;48:4006-8
   PubMed Web of Science ®Google Scholar
• Lin CC, Luu K, Lourenco D, Pharmacokinetics and metabolism of [14C] viramidine in rats and cynomolgus monkeys. Antimicrob Agents Chemother 2003;47:2458-63
   PubMed Web of Science ®Google Scholar
• Lin CC, Lourenco D, Xu G, Disposition and metabolic profiles of [14C] viramidine and [14C] ribavirin in rat and monkey red blood cells and liver. Antimicrob Agents Chemother 2004;48:1872-5
   PubMed Web of Science ®Google Scholar
• Lin CC, Xu C, Zhu N, Absorption, metabolism, and excretion of [14C] viramidine in humans. Antimicrob Agents Chemother 2006;50:2368-73
   PubMed Web of Science ®Google Scholar
• Lin CC, Philips L, Xu C, Pharmacokinetics and safety of viramidine, a prodrug of ribavirin, in healthy volunteers. J Clin Pharmacol 2004;44:265-75
   PubMed Web of Science ®Google Scholar
• Aora S, Xu C, Teng A, Ascending multiple-dose pharmacokinetics of viramidine, a prodrug of ribavirin, in adult subjects with compensated hepatitis c infection. J Clin Pharmacol 2005;45:275-85
   PubMed Web of Science ®Google Scholar
• Li L, Koo SH, Limenta LM, Effect of dietary purines on the pharmacokinetics of orally administered ribavirin. J Clin Pharmacol 2009;49(6):661-7
   PubMed Web of Science ®Google Scholar
• Gish RG, Arora S, Reddy KR, Virological response and safety outcomes in therapy-naive patients treated for chronic hepatitis C with taribavirin or ribavirin in combination with pegylated interferon alfa-2a: a randomized, phase 2 study. J Hepatol 2007;47:51-9
   PubMed Web of Science ®Google Scholar
• Behnamou Y, Afdhal NH, Nelson DR. A phase III study of the safety and efficacy of viramidine versus ribavirin in treatment-naive patients with chronic hepatitis C: ViSER1 results. Hepatology 2009;50:717-26
   PubMed Web of Science ®Google Scholar
• Marcellin P, Gish RG, Gitlin N, The safety and efficacy of taribavirin plus pegylated interferon alfa-2a versus ribavirin plus pegylated interferon alfa-2a in therapy-naive patients infected with HCV: phase 3 results. J Hepatol 2010;52:32-8
   PubMedGoogle Scholar
• Poordad F, Lawitz E, Shiffman ML, Virologic response rates of weight-based taribavirin versus ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C. Hepatology 2010;52:1185-8
   PubMedGoogle Scholar
• Jacobson IM, Brown RS Jr, McCone J, Impact of weight-based ribavirin with peginterferon alfa-2b in African Americans with hepatitis C virus genotype 1. Hepatology 2007;46:982-90
   PubMed Web of Science ®Google Scholar
• Fried MW, Jensen DM, Rodriquez-Torres M, Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: randomized study of higher doses of peginterferon alpha-2a and ribavirin. Hepatology 2008;48:1033-43
   PubMed Web of Science ®Google Scholar
• Zopf S, Herold C, Hahn EG, Peginterferon alfa-2a relapse rates depend on weight-based ribavirin dosage in HCV-infected patients with genotype 1: results of a retrospective evaluation. Scand J Gastroenterol 2009;44:486-90
   PubMed Web of Science ®Google Scholar
• Lindahl K, Stahle L, Bruchfeld A, High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C. Hepatology 2005;41:275-9
   PubMed Web of Science ®Google Scholar
• Blackard JT, Kemmer N, Sherman KE. Extrahepatic replication of HCV: insights into clinical manifestations and biological consequences. Hepatology 2006;44:15-22
   PubMed Web of Science ®Google Scholar
• Gallegos-Orozco JF, Rakela J, Rosati MJ, Persistence of hepatitis C virus in peripheral blood mononuclear cells of sustained viral responders to pegylated interferon and ribavirin therapy. Dig Dis Sci 2008;53:2564-8
   PubMed Web of Science ®Google Scholar
• Radkowski M, Gallegos-Orozco JF, Jablonska J, Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C. Hepatology 2005;41:106-14
   PubMed Web of Science ®Google Scholar
• Pham TNQ, MacParland SA, Mulrooney PM, Hepatitis C virus persistence after spontaneous or treatment-induced resolution of hepatitis C. J Virol 2004;78:5867-74
   PubMed Web of Science ®Google Scholar
• Mazur W, Mazurek U, Jurzak M, Positive and negative strands of HCV-RNA in sera and peripheral blood mononuclear cells of chronically hemodialyzed patients. Med Sci Monit 2001;7:108-15
   PubMedGoogle Scholar
• Ramirez S, Perez-del-Pulgar S, Forns X. Virology and pathogenesis of hepatitis C virus recurrence. Liver Transpl 2008;14(Suppl 2):S27-35
   Google Scholar
• de Felipe B, Leal M, Soriano-Sarabia N, HCV RNA in peripheral blood cell subsets in HCV-HIV coinfected patients at the end of PegIFN/RBV treatment is associated with virologic relapse. J Viral Hepat 2009;16:21-7
   PubMed Web of Science ®Google Scholar
• Morello J, Soriano V, Barreiro P, Plasma ribavirin trough concentrations at week 4 predict hepatitis C virus (HCV) relapse in HIV-HCV-coinfected patients treated for chronic hepatitis C. Antimicrob Agents Chemother 2010;54:1647-9
   PubMed Web of Science ®Google Scholar